創薬市場における人工知能（AI） – 2029年までの世界予測

Report Overview

The global artificial intelligence (AI) in drug discovery market is projected to reach 6.89 billion by 2029 from 1.86 billion in 2024, at a CAGR of 29.9% from 2024 to 2029.

創薬市場における世界の人工知能 (AI) は、2024 年の 18 億 6000 万から 2029 年までに 68 億 9000 万に達し、2024 年から 2029 年までの CAGR は 29.9% になると予測されています。

Increasing cross-industry collaborations and partnerships drive the growth of the artificial intelligence (AI) in drug discovery market by combining expertise, resources, and technology from various aspects of the drug discovery supply chain. For instance, in March 2024, Cognizant collaborated with NVIDIA to use generative AI through the BioNeMo platform, with the goal of transforming drug discovery and accelerating the development of life-saving therapies. Similarly, in August 2024, Exscientia Recursion and Exscientia plc announced a agreement, combining their technologies to enhance drug discovery. The integrated Recursion OS will enhance drug discovery through patient-centric target discovery, AI-driven design, quantum mechanics modeling, automated chemical synthesis, and other features. The combined company plans to complete 10 clinical trials within 18 months. Exscientia shareholders will receive Recursion stock, with Recursion shareholders owning 74% of the combined company. The deal is worth USD 850M in cash and is expected to close by early 2025.

“Oncology held the largest market share in the artificial intelligence (AI) in drug discovery market, by therapeutic area in 2023.”

Based on therapeutic areas, the artificial intelligence (AI) in drug discovery market is segmented into oncology, infectious diseases, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health, and others (respiratory diseases, nephrology, dermatological diseases, genetic disorders, inflammatory diseases, and gastrointestinal). The oncology segment held the largest market share in the artificial intelligence (AI) in drug discovery market due to high prevalence of cancer and the complex nature of tumor biology, which necessitates innovative approaches for drug development. There were approximately 20 million new cancer cases and 9.7 million cancer-related deaths worldwide in 2022. Similarly, in 2024, 2.0 million new cancer cases and 611,720 cancer deaths are projected to occur in the US. The growing availability of biomedical data from cancer research, patient records, genomic studies, multi-omics datasets (genomics, proteomics, transcriptomics), and clinical trials provides an opportunity to leverage AI for pattern recognition and predicting drug interactions. The high demand for personalized medicine and targeted therapies in oncology, large commercial returns, emerging focus on immuno-oncology (especially checkpoint inhibitors and T-cell therapies), and exhaustive data availability drive investment in Al-driven solutions, elevating it to the forefront of the drug discovery landscape.

“Understanding disease use case to witness the fastest growth during the forecast period.”

Based on the use case, artificial intelligence (AI) in drug discovery market is segmented into understanding the disease, drug repurposing, de novo drug design, drug optimization, and safety & toxicity. The understanding disease is poised to be the fastest-growing use case over the forecast period. AI’s capacity to assess complex biological data and identify disease mechanisms is critical in early-stage drug development. AI helps researchers better understand disease pathways, genetic factors, and biomarkers, all of which are necessary for developing targeted therapies. Understanding diseases is required to identify potential drug targets, which enhances the efficiency of subsequent stages such as drug design and testing. The growth use of AI for phenotypic screening, image analysis, detecting anomalies in genetic perturbations on cellular or tissue morphology, biomarker identification, (-omics) data mining is expected to fuel the market growth.

“North America to dominate the market over the forecast period.”

Based on the region, the artificial intelligence (AI) in drug discovery market is segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American region dominated the artificial intelligence (AI) in drug discovery market in 2023. Several factors contribute to this dominance, including significant investment in healthcare technology, strong cross-sector collaborations, the presence of large pharmaceutical and biotechnology companies, and a favorable regulatory environment. The total investments in AI in Drug Development companies are USD 60.2 billion as of March 2023. A large wave of proof-of-concept studies and substantial advances in democratizing AI technology are also propelling the growth of the market. For example, in January 2023, AbSci created and validated de novo antibodies in silico with generative Al. Furthermore, in February 2023, the FDA granted an Orphan Drug Designation to a drug discovered and designed with Al. Insilico Medicine and began a global Phase I trial for the drug.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Designation – Demand Side: Purchase Managers (45%), Heads of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%), and Research Scientists (25%)
• By Designation – Supply Side: C-level Excecutives & Director level (35%), Managers (40%), and Others (25%)
• By Region: North America (45%), Europe (30%), Asia Pacific (20%), and Rest of the world (5%)

List of Companies Profiled in the Report

o               NVIDIA Corporation (US)

o               Exscientia (UK)

o               Google (US)

o               BenevolentAI (UK)

o               Recursion (US)

o               Insilico Medicine (US)

o               Schrödinger, Inc. (US)

o               Microsoft (US)

o               Atomwise Inc. (US)

o               Illumina, Inc. (US)

o               Numedii, Inc. (US)

o               Xtalpi Inc. (US)

o               Iktos (France)

o               Tempus (US)

o               DEEP GENOMICS (Canada)

o               Verge Genomics (US)

o               BenchSci (Canada)

o               Insitro (US)

o               Valo Health (US)

o               BPGBio, Inc. (US)

o               Merck KGaA (Germany)

o               IQVIA (US)

o               Tencent Holdings Limited (China)

o               Predictive Oncology, Inc. (US)

o               CytoReason (Israel)

o               Owkin, Inc. (US)

o               Cloud Pharmaceuticals (US)

o               Evaxion Biotech (Denmark)

o               Standigm (South Korea)

o               BIOAGE (US)

o               Envisagenics (US)

o               Abcellera (US)

o               Centella (India)

The study includes an in-depth competitive analysis of these key players in the artificial intelligence (AI) in drug discovery market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the artificial intelligence (AI) in drug discovery market by process (target identification & selection, target validation, hit identification & prioritization, hit-to-lead identification/lead generation, lead optimization, and candidate selection & validation), by use case (understanding disease, drug repurposing, de novo drug design [small molecule design, vaccines design, antibody & other biologics design], drug optimization [small molecule optimization, vaccines optimization, antibody & other biologics optimization], and safety and toxicity), by therapeutic area (oncology, infectious diseases, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health, others), by player type (end-to-end solution providers, niche/point solutions providers, AI technology providers, business process service providers), by tools (machine learning, natural language processing, context-aware process and computing, computer vision, image analysis (including optical character recognition)), by deployment (on-premise, cloud-based, SaaS-based), by end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), and research centers, academic institutes, & government organizations) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the artificial intelligence (AI) in drug discovery market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services, key strategies such as product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and other recent developments associated with the artificial intelligence (AI) in drug discovery market. Competitive analysis of upcoming startups in the artificial intelligence (AI) in drug discovery market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the artificial intelligence (AI) in drug discovery market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, patent expiry of several drugs, AI application in oncology areas, integration of multi-omics data, initiatives for research on rare diseases and orphan drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software, interpretability of AI), opportunities (growing biotechnology industry, increasing focus on emerging markets, focus on developing human-aware AI systems, increasing use of AI in single cell analysis, rapid expansion of biomarker, disease types, and subtypes identification, growing demand for precision and personalized medicine), and challenges (limited availability of data sets, lack of required tools and usability, computational limitations of advanced AI models, challenges regarding the accessibility of high-quality data) influencing the growth of the artificial intelligence (AI) in drug discovery market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the artificial intelligence (AI) in drug discovery market
• Market Development: Comprehensive information about lucrative markets – the report analyses the artificial intelligence (AI) in drug discovery market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the artificial intelligence (AI) in drug discovery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Numedii, Inc. (US), Xtalpi Inc. (US), Iktos (France), Valo Health (US), and Merck KGaA (Germany), among others in artificial intelligence (AI) in drug discovery market.

Table of Contents

1               INTRODUCTION              39

1.1           STUDY OBJECTIVES       39

1.2           MARKET DEFINITION   39

1.3           STUDY SCOPE   40

1.3.1        SEGMENTS AND REGIONS CONSIDERED              40

1.3.2        INCLUSIONS AND EXCLUSIONS 41

1.3.3        YEARS CONSIDERED      42

1.3.4        CURRENCY CONSIDERED            42

1.4           MARKET STAKEHOLDERS            43

1.5           SUMMARY OF CHANGES               44

2               RESEARCH METHODOLOGY       45

2.1           RESEARCH DATA              45

2.1.1        SECONDARY DATA          46

2.1.1.1    Key secondary sources         46

2.1.1.2    Key data from secondary sources       47

2.1.2        PRIMARY DATA 47

2.1.2.1    Key primary sources             48

2.1.2.2    Key objectives of primary research    48

2.1.2.3    Key data from primary sources           49

2.1.2.4    Key industry insights           50

2.1.2.5    Breakdown of primaries      50

2.2           RESEARCH DESIGN         51

2.3           MARKET SIZE ESTIMATION         51

2.3.1        SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)                 52

2.3.2        BOTTOM-UP APPROACH: END-USER ADOPTION                 54

2.3.2.1    Top-down assessment of parent market           55

2.3.2.2    Company presentations and primary interviews              55

2.4           DATA TRIANGULATION                59

2.5           STUDY ASSUMPTIONS  60

2.5.1        MARKET SIZING ASSUMPTIONS                60

2.5.2        RESEARCH ASSUMPTIONS           60

2.6           RISK ASSESSMENT           61

2.7           RESEARCH LIMITATIONS             61

2.7.1        METHODOLOGY-RELATED LIMITATIONS           61

2.7.2        SCOPE-RELATED LIMITATIONS                 61

3               EXECUTIVE SUMMARY  62

4               PREMIUM INSIGHTS       68

4.1           ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW       68

4.2           NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER AND COUNTRY (2023)        69

4.3           ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES       70

4.4           ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL MIX              71

4.5           ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEVELOPED VS.

EMERGING MARKETS    71

5               MARKET OVERVIEW       72

5.1           INTRODUCTION              72

5.2           MARKET DYNAMICS       72

5.2.1        DRIVERS               74

5.2.1.1    Increasing number of cross-industry collaborations and partnerships           74

5.2.1.2    Rising need to reduce time and cost of drug discovery and development          76

5.2.1.3    Patent expiry of drugs and need for effective new leads                 76

5.2.1.4    Growing utilization of AI to predict drug-target interactions for cancer therapy       77

5.2.1.5    Integration of AI-assisted multiomics in drug discovery                 78

5.2.1.6    Growing focus on rare disease treatments for orphan drug development          79

5.2.2        RESTRAINTS      80

5.2.2.1    Shortage of AI workforce and ambiguous regulatory guidelines for medical software             80

5.2.3        OPPORTUNITIES              81

5.2.3.1    Leveraging AI for accelerated biotech drug discovery    81

5.2.3.2    Increased focus on drug discovery in emerging economies                 81

5.2.3.3    Focus on developing human-aware AI systems                82

5.2.3.4    Growing use of AI in single-cell analysis          82

5.2.3.5    Easy identification of biomarker and disease subtypes from single-cell data      83

5.2.3.6    High demand for precision and personalized medicines                 84

5.2.4        CHALLENGES    85

5.2.4.1    Limited availability of quality data sets             85

5.2.4.2    Lack of advanced AI tools and training data sets             85

5.2.4.3    Computational constraints of advanced AI models         86

5.2.4.4    Lack of high-quality data sets for model training            86

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            87

5.4           INDUSTRY TRENDS         87

5.4.1        EVOLUTION OF AI IN DRUG DISCOVERY              87

5.4.2        COMPUTER-AIDED DRUG DESIGN AND ARTIFICIAL INTELLIGENCE 89

5.5           ECOSYSTEM ANALYSIS  91

5.6           SUPPLY CHAIN ANALYSIS             93

5.7           TECHNOLOGY ANALYSIS             94

5.7.1        KEY TECHNOLOGIES     94

5.7.1.1    Dry lab services    94

5.7.1.2    Wet lab services    97

5.7.1.2.1 Chemistry software and services        97

5.7.1.2.2 Biology software and services             98

5.7.1.2.2.1              Single-cell analysis                99

5.7.2        COMPLEMENTARY TECHNOLOGIES       102

5.7.2.1    High-performance computing            102

5.7.2.2    Next-generation sequencing               102

5.7.2.3    Real-world evidence/Real-world data                102

5.7.3        ADJACENT TECHNOLOGIES       103

5.7.3.1    Cloud computing  103

5.7.3.2    Blockchain technologies      103

5.7.3.3    Internet of things 103

5.8           REGULATORY LANDSCAPE         104

5.8.1        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             104

5.8.2        REGULATORY FRAMEWORK       107

5.9           PRICING ANALYSIS          111

5.9.1        INDICATIVE SELLING PRICE FOR DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION 111

5.9.2        INDICATIVE PRICING ANALYSIS, BY PROCESS    112

5.10         PORTER’S FIVE FORCES ANALYSIS           112

5.10.1      INTENSITY OF COMPETITIVE RIVALRY 114

5.10.2      BARGAINING POWER OF BUYERS             114

5.10.3      THREAT OF SUBSTITUTES          114

5.10.4      THREAT OF NEW ENTRANTS      114

5.10.5      BARGAINING POWER OF SUPPLIERS       115

5.11         KEY STAKEHOLDERS AND BUYING CRITERIA     115

5.11.1      KEY STAKEHOLDERS IN BUYING PROCESS           115

5.11.2      KEY BUYING CRITERIA  116

5.12         PATENT ANALYSIS          117

5.12.1      PATENT PUBLICATION TRENDS               117

5.12.2      JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY  117

5.12.3      MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET        119

5.13         UNMET NEEDS AND KEY PAIN POINTS  121

5.13.1      UNMET NEEDS 121

5.13.2      SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY               122

5.13.3      END-USER EXPECTATIONS         123

5.14         KEY CONFERENCES & EVENTS, 2024–2025              124

5.15         CASE STUDY ANALYSIS 125

5.16         BUSINESS MODEL ANALYSIS      130

5.17         INVESTMENT AND FUNDING SCENARIO               132

5.18         IMPACT OF AI/GENERATIVE AI ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET  133

5.18.1      TOP USE CASES AND MARKET POTENTIAL          133

5.18.1.1  Key use cases         134

5.18.2      CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION         135

5.18.2.1  Case study 1: Accelerated drug discovery with generative AI and streamlined workflows         135

5.18.2.2  Case study 2: Accelerating small-molecule drug discovery with generative AI         135

5.18.3      IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS   136

5.18.3.1  AI in drug discovery market                136

5.18.3.2  Genomics and bioinformatics market                137

5.18.3.3  Life science analytics market              137

5.18.4      USER READINESS AND IMPACT ASSESSMENT     138

5.18.4.1  User readiness       138

5.18.4.1.1                Pharmaceutical companies 138

5.18.4.1.2                Biotechnology companies   138

5.18.4.2  Impact assessment                138

5.18.4.2.1                User A: Pharmaceutical Companies  138

5.18.4.2.1.1            Implementation    138

5.18.4.2.1.2            Impact    139

5.18.4.2.2                User B: Biotechnology companies     139

5.18.4.2.2.1            Implementation    139

5.18.4.2.2.2            Impact    139

5.19         ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS                 140

6               ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS   150

6.1           INTRODUCTION              151

6.2           TARGET IDENTIFICATION & SELECTION              152

6.2.1        INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH          152

6.3           TARGET VALIDATION   153

6.3.1        RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH       153

6.4           HIT IDENTIFICATION & PRIORITIZATION            154

6.4.1        NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION         154

6.5           HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION                 155

6.5.1        HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY 155

6.6           LEAD OPTIMIZATION   156

6.6.1        NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH              156

6.7           CANDIDATE SELECTION & VALIDATION              157

6.7.1        HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES                 157

7               ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE  159

7.1           INTRODUCTION              160

7.2           UNDERSTANDING DISEASES      161

7.2.1        INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY   161

7.3           DRUG REPURPOSING    162

7.3.1        INCREASING NEED FOR COST-EFFECTIVE TREATMENTS AND RISING AVAILABILITY OF BIOMEDICAL DATA TO AID MARKET GROWTH             162

7.4           DE NOVO DRUG DESIGN              163

7.4.1        SMALL-MOLECULE DESIGN        164

7.4.1.1    Increasing use of virtual screening and simulation techniques to drive growth          164

7.4.2        VACCINE DESIGN            165

7.4.2.1    Availability of well-validated AI tools to boost market growth                 165

7.4.3        ANTIBODY & OTHER BIOLOGICS DESIGN            165

7.4.3.1    Advancements in protein modeling to propel segment growth                 165

7.5           DRUG OPTIMIZATION  166

7.5.1        SMALL-MOLECULE OPTIMIZATION        167

7.5.1.1    Leveraging generative models for identifying potential modifications in molecular structures to aid market growth          167

7.5.2        VACCINE OPTIMIZATION            168

7.5.2.1    Effectively predicting vaccine formulations and adjusting delivery vectors to drive growth        168

7.5.3        ANTIBODY & OTHER BIOLOGICS OPTIMIZATION                 169

7.5.3.1    Increasing adoption of machine learning for predicting protein structures to augment segment growth             169

7.6           SAFETY & TOXICITY       170

7.6.1        FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET 170

8               ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA                172

8.1           INTRODUCTION              173

8.2           ONCOLOGY        173

8.2.1        HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO PROPEL MARKET GROWTH                 173

8.3           INFECTIOUS DISEASES 175

8.3.1        RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY   175

8.4           NEUROLOGY     177

8.4.1        COMPLEX DISEASE DIAGNOSIS AND TREATMENT TO INCREASE ADOPTION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY        177

8.5           METABOLIC DISEASES  178

8.5.1        ROLE OF ARTIFICIAL INTELLIGENCE IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION   178

8.6           CARDIOVASCULAR DISEASES    179

8.6.1        SEDENTARY LIFESTYLES AND HIGH PREVALENCE OF OBESITY TO INCREASE NOVEL DRUG DEVELOPMENT FOR CARDIAC DISEASES        179

8.7           IMMUNOLOGY 180

8.7.1        GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH           180

8.8           MENTAL HEALTH DISORDERS  180

8.8.1        INCREASED OCCURRENCE OF MENTAL HEALTH DISEASES IN DEVELOPED ECONOMIES TO SPUR MARKET GROWTH             180

8.9           OTHER THERAPEUTIC AREAS    181

9               ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE          182

9.1           INTRODUCTION              183

9.2           END-TO-END SOLUTION PROVIDERS    183

9.2.1        END-TO-END SOLUTION PROVIDERS TO REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS     183

9.3           NICHE/POINT SOLUTION PROVIDERS   184

9.3.1        ACCURATE, COST-EFFECTIVE, AND LESS TIME CONSUMPTION TO PROPEL MARKET GROWTH                184

9.4           AI TECHNOLOGY PROVIDERS    185

9.4.1        SPECIALIZED AI CAPABILITIES WITH FULL-SERVICE MANAGEMENT TO SUPPORT MARKET GROWTH              185

9.5           BUSINESS PROCESS SERVICE PROVIDERS             186

9.5.1        BETTER ACCESSIBILITY OF HIGH-QUALITY TOOLS AND LOWER DRUG DEVELOPMENT COSTS TO AID MARKET GROWTH             186

10            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL    187

10.1         INTRODUCTION              188

10.2         MACHINE LEARNING     188

10.2.1      DEEP LEARNING               190

10.2.1.1  Reduced number of errors and consistent management of data to augment market growth      190

10.2.1.2  Convolutional neural networks           191

10.2.1.3  Recurrent neural networks 191

10.2.1.4  Generative adversarial networks        191

10.2.1.5  Graph neural networks        191

10.2.1.6  Other deep learning technologies      192

10.2.2      SUPERVISED LEARNING                192

10.2.2.1  Supervised learning to predict drug repositioning and manage high-dimensional datasets  192

10.2.3      REINFORCEMENT LEARNING     193

10.2.3.1  Need to accelerate new molecules and maximize performance to augment segment growth    193

10.2.4      UNSUPERVISED LEARNING         194

10.2.4.1  Unsupervised learning to perform complex tasks, uncover potential drug candidates, and optimize lead compounds             194

10.2.5      OTHER MACHINE LEARNING TECHNOLOGIES  195

10.3         NATURAL LANGUAGE PROCESSING       196

10.3.1      NATURAL LANGUAGE PROCESSING TO IDENTIFY INFORMATION WITHIN UNSTRUCTURED DATA AND ACCELERATE DRUG DISCOVERY              196

10.4         CONTEXT-AWARE PROCESSING & COMPUTING                 197

10.4.1      CONTEXT-AWARE COMPUTING TO IMPROVE PREDICTIONS OF PATIENT-SPECIFIC DRUG RESPONSES AND OPTIMIZE THERAPEUTIC INTERVENTIONS        197

10.5         COMPUTER VISION        198

10.5.1      COMPUTER VISION TO ENHANCE DRUG DISCOVERY THROUGH ADVANCED IMAGE PROCESSING      198

10.6         IMAGE ANALYSIS              198

10.6.1      BETTER DRUG DISCOVERY THROUGH IMAGE PROCESSING TECHNIQUES TO SUPPORT MARKET GROWTH                 198

11            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT        200

11.1         INTRODUCTION              201

11.2         ON-PREMISES DEPLOYMENT     201

11.2.1      PROVISION OF MULTI-VENDOR ARCHITECTURE AND SECURITY BENEFITS TO DRIVE MARKET               201

11.3         CLOUD-BASED DEPLOYMENT  202

11.3.1      FOCUS ON RESEARCH COLLABORATIONS AND ELIMINATION OF SOFTWARE AND HARDWARE PURCHASING COSTS TO DRIVE MARKET           202

11.4         SAAS-BASED DEPLOYMENT        204

11.4.1      LOWER COSTS, BETTER SECURITY, AND EASIER ACCESS TO AUGMENT MARKET GROWTH            204

12            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 206

12.1         INTRODUCTION              207

12.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 207

12.2.1      RISING DEMAND FOR COST-EFFECTIVE DRUG DEVELOPMENT TO PROPEL MARKET GROWTH                207

12.3         CONTRACT RESEARCH ORGANIZATIONS             210

12.3.1      RISING NEED FOR OUTSOURCING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES TO AID MARKET GROWTH          210

12.4         RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES       211

12.4.1      FOCUS ON DEVELOPING THERAPEUTIC STRATEGIES AND INNOVATIVE APPROACHES IN DRUG DISCOVERY TO AID MARKET GROWTH          211

13            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION     213

13.1         INTRODUCTION              214

13.2         NORTH AMERICA             214

13.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 214

13.2.2      US           220

13.2.2.1  US to dominate North American market during study period                 220

13.2.3      CANADA               226

13.2.3.1  Emergence of new AI-based startups and high health expenditure to support market growth    226

13.3         EUROPE               231

13.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      232

13.3.2      UK          237

13.3.2.1  Favorable government R&D funding to augment market growth                 237

13.3.3      GERMANY           243

13.3.3.1  Presence of advanced medical infrastructure and high focus on personalized medicines to drive market            243

13.3.4      FRANCE                248

13.3.4.1  Strong government support and favorable strategies to propel market growth       248

13.3.5      ITALY    253

13.3.5.1  Advanced pharmaceutical industry and increased focus on life science R&D to fuel market growth   253

13.3.6      SPAIN    258

13.3.6.1  Favorable government initiatives and high investments by pharmaceutical companies to boost market growth        258

13.3.7      REST OF EUROPE             263

13.4         ASIA PACIFIC     269

13.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 269

13.4.2      JAPAN   275

13.4.2.1  High geriatric population and advanced pharmaceutical research to boost market growth        275

13.4.3      CHINA  281

13.4.3.1  Increasing demand for generics and rising government investments to propel market growth                281

13.4.4      INDIA    286

13.4.4.1  Developed IT infrastructure and favorable government initiatives to spur market growth          286

13.4.5      REST OF ASIA PACIFIC   291

13.5         LATIN AMERICA                296

13.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 297

13.5.2      BRAZIL 302

13.5.2.1  Growing biotechnology sector and increasing governmental initiatives to boost market growth     302

13.5.3      MEXICO                307

13.5.3.1  Favorable government initiatives and high investments by pharmaceutical companies to support market growth    307

13.5.4      REST OF LATIN AMERICA             312

13.6         MIDDLE EAST & AFRICA                317

13.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 318

13.6.2      GCC COUNTRIES              323

13.6.2.1  Increasing emphasis on personalized medicines and developing healthcare infrastructure to drive market         323

13.6.3      REST OF MIDDLE EAST & AFRICA             328

14            COMPETITIVE LANDSCAPE         334

14.1         INTRODUCTION              334

14.2         KEY PLAYER STRATEGY/RIGHT TO WIN                334

14.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET                 334

14.3         REVENUE ANALYSIS, 2019–2023  336

14.4         MARKET SHARE ANALYSIS, 2023                 337

14.4.1      RANKING OF KEY MARKET PLAYERS       339

14.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 340

14.5.1      STARS   340

14.5.2      EMERGING LEADERS     340

14.5.3      PERVASIVE PLAYERS      340

14.5.4      PARTICIPANTS 340

14.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         342

14.5.5.1  Company footprint               342

14.5.5.2  Use case footprint 343

14.5.5.3  Process footprint  344

14.5.5.4  Therapeutic area footprint  345

14.5.5.5  Player type footprint            346

14.5.5.6  Deployment mode footprint                347

14.5.5.7  Region footprint   348

14.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        349

14.6.1      PROGRESSIVE COMPANIES         349

14.6.2      RESPONSIVE COMPANIES            349

14.6.3      DYNAMIC COMPANIES  349

14.6.4      STARTING BLOCKS         349

14.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 351

14.7         COMPANY VALUATION AND FINANCIAL METRICS                 352

14.7.1      FINANCIAL METRICS      352

14.7.2      COMPANY VALUATION 353

14.8         BRAND/PRODUCT COMPARISON             354

14.9         COMPETITIVE SCENARIO             355

14.9.1      PRODUCT AND SOLUTION LAUNCHES 355

14.9.2      DEALS  356

14.9.3      EXPANSIONS     357

14.9.4      OTHER DEVELOPMENTS              358

15            COMPANY PROFILES      359

15.1         KEY PLAYERS     359

15.1.1      NVIDIA CORPORATION 359

15.1.1.1  Business overview 359

15.1.1.2  Products/Services/Solutions offered 360

15.1.1.3  Recent developments           361

15.1.1.3.1                Product and service launches             361

15.1.1.3.2                Deals      363

15.1.1.4  MnM view              367

15.1.1.4.1                Right to win           367

15.1.1.4.2                Strategic choices   367

15.1.1.4.3                Weaknesses and competitive threats 367

15.1.2      EXSCIENTIA       368

15.1.2.1  Business overview 368

15.1.2.2  Products/Services/Solutions offered 369

15.1.2.3  Recent developments           371

15.1.2.3.1                Solution launches 371

15.1.2.3.2                Deals      371

15.1.2.3.3                Expansions             377

15.1.2.3.4                Other developments             378

15.1.2.4  MnM view              379

15.1.2.4.1                Right to win           379

15.1.2.4.2                Strategic choices   379

15.1.2.4.3                Weaknesses and competitive threats 379

15.1.3      GOOGLE              380

15.1.3.1  Business overview 380

15.1.3.2  Products/Services/Solutions offered 381

15.1.3.3  Recent developments           382

15.1.3.3.1                Solution launches 382

15.1.3.3.2                Deals      383

15.1.3.3.3                Expansions             384

15.1.3.4  MnM view              384

15.1.3.4.1                Right to win           384

15.1.3.4.2                Strategic choices   384

15.1.3.4.3                Weaknesses and competitive threats 384

15.1.4      RECURSION        385

15.1.4.1  Business overview 385

15.1.4.2  Products/Services/Solutions offered 386

15.1.4.3  Recent developments           386

15.1.4.3.1                Solution launches 386

15.1.4.3.2                Deals      387

15.1.4.3.3                Expansions             388

15.1.4.4  MnM view              389

15.1.4.4.1                Right to win           389

15.1.4.4.2                Strategic choices made        389

15.1.4.4.3                Weaknesses and competitive threats 389

15.1.5      INSILICO MEDICINE       390

15.1.5.1  Business overview 390

15.1.5.2  Products/Services/Solutions offered 390

15.1.5.3  Recent developments           392

15.1.5.3.1                Product and solution launches and developments                 392

15.1.5.3.2                Deals      393

15.1.5.3.3                Other developments             398

15.1.5.4  MnM view              399

15.1.5.4.1                Right to win           399

15.1.5.4.2                Strategic choices   399

15.1.5.4.3                Weaknesses and competitive threats 399

15.1.6      SCHRÖDINGER, INC.      400

15.1.6.1  Business overview 400

15.1.6.2  Products/Services/Solutions offered 401

15.1.6.3  Recent developments           402

15.1.6.3.1                Deals      402

15.1.6.3.2                Other developments             405

15.1.7      BENEVOLENTAI               406

15.1.7.1  Business overview 406

15.1.7.2  Products/Services/Solutions offered 407

15.1.7.3  Recent developments           407

15.1.7.3.1                Deals      407

15.1.8      MICROSOFT CORPORATION      409

15.1.8.1  Business overview 409

15.1.8.2  Products/Services/Solutions offered 410

15.1.8.3  Recent developments           411

15.1.8.3.1                Deals      411

15.1.9      ATOMWISE INC.                413

15.1.9.1  Business overview 413

15.1.9.2  Products/Services/Solutions offered 413

15.1.9.3  Recent developments           414

15.1.9.3.1                Deals      414

15.1.10   ILLUMINA, INC. 415

15.1.10.1                 Business overview 415

15.1.10.2                 Products/Services/Solutions offered 416

15.1.10.3                 Recent developments           417

15.1.10.3.1             Solution launches 417

15.1.10.3.2             Deals      418

15.1.11   NUMEDII, INC.  420

15.1.11.1                 Business overview 420

15.1.11.2                 Products/Services/Solutions offered 420

15.1.12   XTALPI INC.       421

15.1.12.1                 Business overview 421

15.1.12.2                 Products/Services/Solutions offered 421

15.1.12.3                 Recent developments           422

15.1.12.3.1             Deals      422

15.1.13   IKTOS   424

15.1.13.1                 Business overview 424

15.1.13.2                 Products/Services/Solutions offered 425

15.1.13.3                 Recent developments           426

15.1.13.3.1             Deals      426

15.1.13.3.2             Other developments             429

15.1.14   TEMPUS               430

15.1.14.1                 Business overview 430

15.1.14.2                 Products/Services/Solutions offered 430

15.1.14.3                 Recent developments           431

15.1.14.3.1             Solution launches 431

15.1.14.3.2             Deals      432

15.1.14.3.3             Expansions             435

15.1.14.3.4             Other developments             435

15.1.15   DEEP GENOMICS             436

15.1.15.1                 Business overview 436

15.1.15.2                 Products/Services/Solutions offered 436

15.1.15.3                 Recent developments           437

15.1.15.3.1             Solution launches 437

15.1.15.3.2             Deals      437

15.1.15.3.3             Other developments             437

15.1.16   VERGE GENOMICS          438

15.1.16.1                 Business overview 438

15.1.16.2                 Products/Services/Solutions offered 438

15.1.16.3                 Recent developments           439

15.1.16.3.1             Deals      439

15.1.17   BENCHSCI           440

15.1.17.1                 Business overview 440

15.1.17.2                 Products/Services/Solutions offered 440

15.1.17.3                 Recent developments           441

15.1.17.3.1             Solution launches 441

15.1.17.3.2             Deals      441

15.1.17.3.3             Other developments             441

15.1.18   INSITRO               442

15.1.18.1                 Business overview 442

15.1.18.2                 Products/Services/Solutions offered 442

15.1.18.3                 Recent developments           443

15.1.18.3.1             Deals      443

15.1.18.3.2             Other developments             443

15.1.19   VALO HEALTH  444

15.1.19.1                 Business overview 444

15.1.19.2                 Products/Services/Solutions offered 444

15.1.19.3                 Recent developments           445

15.1.19.3.1             Deals      445

15.1.19.3.2             Other developments             446

15.1.20   BPGBIO, INC.     447

15.1.20.1                 Business overview 447

15.1.20.2                 Products/Services/Solutions offered 447

15.1.20.3                 Recent developments           448

15.1.20.3.1             Deals      448

15.1.21   MERCK KGAA    449

15.1.21.1                 Business overview 449

15.1.21.2                 Products/Services/Solutions offered 450

15.1.21.3                 Recent developments           451

15.1.21.3.1             Solution launches 451

15.1.21.3.2             Deals      451

15.1.21.3.3             Expansions             452

15.1.21.3.4             Other developments             453

15.2         OTHER PLAYERS              454

15.2.1      PREDICTIVE ONCOLOGY             454

15.2.2      IQVIA INC.           455

15.2.3      TENCENT HOLDINGS LIMITED 456

15.2.4      CYTOREASON LTD.         457

15.2.5      OWKIN, INC.       458

15.2.6      CLOUD PHARMACEUTICALS      459

15.2.7      EVAXION BIOTECH A/S 460

15.2.8      STANDIGM INC.                461

15.2.9      BIOAGE LABS    462

15.2.10   ENVISAGENICS 463

15.2.11   ABCELLERA        464

15.2.12   CENTELLA          465

16            APPENDIX           466

16.1         DISCUSSION GUIDE        466

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                474

16.3         CUSTOMIZATION OPTIONS        476

16.4         RELATED REPORTS         476

16.5         AUTHOR DETAILS           477

LIST OF TABLES

TABLE 1                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:

INCLUSIONS AND EXCLUSIONS 41

TABLE 2                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2023           43

TABLE 3                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: FACTOR ANALYSIS             56

TABLE 4                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: MARKET SIZING ASSUMPTIONS   60

TABLE 5                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RISK ASSESSMENT              61

TABLE 6                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS              73

TABLE 7                INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021–2023            74

TABLE 8                INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 AND 2024              77

TABLE 9                ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM        92

TABLE 10              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 104

TABLE 11              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           105

TABLE 12              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 106

TABLE 13              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 106

TABLE 14              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 107

TABLE 15              NORTH AMERICA: REGULATORY FRAMEWORK                 107

TABLE 16              EUROPE: REGULATORY FRAMEWORK    108

TABLE 17              ASIA PACIFIC: REGULATORY FRAMEWORK                 109

TABLE 18              MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK     110

TABLE 19              LATIN AMERICA: REGULATORY FRAMEWORK                 110

TABLE 20              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE SELLING PRICE, BY REGION, 2021–2023              111

TABLE 21              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE PRICING,

BY PROCESS, 2023             112

TABLE 22              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS                 113

TABLE 23              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP

THREE END USERS (%)  116

TABLE 24              KEY BUYING CRITERIA FOR TOP THREE END USERS   117

TABLE 25              JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY        118

TABLE 26              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: LIST OF PATENTS/PATENT APPLICATIONS 120

TABLE 27              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025     124

TABLE 28              CASE STUDY 1: LEVERAGING AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE 125

TABLE 29              CASE STUDY 2: ARTIFICIAL INTELLIGENCE-DRIVEN DRUG DISCOVERY

AND CO-DEVELOPMENT              126

TABLE 30              CASE STUDY 3: ADVANCING GENE THERAPY FOR RARE NEUROLOGICAL DISEASES    127

TABLE 31              CASE STUDY 4: ARTIFICIAL INTELLIGENCE DESIGN AND OPTIMIZATION OF EXS4318             128

TABLE 32              CASE STUDY 5: ARTIFICIAL INTELLIGENCE-DRIVEN DESIGN AND CLINICAL EVALUATION OF GTAEXS617                 129

TABLE 33              KEY ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS, BY COMPANY               140

TABLE 34              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS,

2022–2029 (USD MILLION)            151

TABLE 35              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2022–2029 (USD MILLION)         153

TABLE 36              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2022–2029 (USD MILLION)            154

TABLE 37              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022–2029 (USD MILLION)                 155

TABLE 38              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022–2029 (USD MILLION) 156

TABLE 39              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)            157

TABLE 40              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022–2029 (USD MILLION)      158

TABLE 41              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 160

TABLE 42              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY REGION, 2022–2029 (USD MILLION)          162

TABLE 43              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG REPURPOSING, BY REGION, 2022–2029 (USD MILLION)            163

TABLE 44              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            163

TABLE 45              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY REGION, 2022–2029 (USD MILLION)            164

TABLE 46              SMALL-MOLECULE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION)          164

TABLE 47              VACCINE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION)       165

TABLE 48              ANTIBODY & OTHER BIOLOGICS DESIGN MARKET, BY REGION,

2022–2029 (USD MILLION)            166

TABLE 49              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            166

TABLE 50              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)            167

TABLE 51              SMALL-MOLECULE OPTIMIZATION MARKET, BY REGION,

2022–2029 (USD MILLION)            168

TABLE 52              VACCINE OPTIMIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)            169

TABLE 53              ANTIBODY & OTHER BIOLOGICS OPTIMIZATION MARKET, BY REGION,

2022–2029 (USD MILLION)            170

TABLE 54              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY REGION, 2022–2029 (USD MILLION)            171

TABLE 55              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            173

TABLE 56              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY,

BY REGION, 2022–2029 (USD MILLION)   175

TABLE 57              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)            176

TABLE 58              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY,

BY REGION, 2022–2029 (USD MILLION)   177

TABLE 59              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2022–2029 (USD MILLION)            178

TABLE 60              INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT          179

TABLE 61              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)          179

TABLE 62              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY,

BY REGION, 2022–2029 (USD MILLION)   180

TABLE 63              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2022–2029 (USD MILLION)          181

TABLE 64              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)          181

TABLE 65              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,

2022–2029 (USD MILLION)            183

TABLE 66              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR END-TO-END SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION)   184

TABLE 67              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION)         185

TABLE 68              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR AI TECHNOLOGY PROVIDERS, BY REGION, 2022–2029 (USD MILLION)          186

TABLE 69              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022–2029 (USD MILLION)         186

TABLE 70              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL,

2022–2029 (USD MILLION)            188

TABLE 71              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       189

TABLE 72              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2022–2029 (USD MILLION)            190

TABLE 73              DEEP LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)       192

TABLE 74              SUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)            193

TABLE 75              REINFORCEMENT LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)          194

TABLE 76              UNSUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)          195

TABLE 77              OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            195

TABLE 78              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022–2029 (USD MILLION)   196

TABLE 79              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & COMPUTING, BY REGION, 2022–2029 (USD MILLION)      197

TABLE 80              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR COMPUTER VISION, BY REGION, 2022–2029 (USD MILLION)            198

TABLE 81              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMAGE ANALYSIS,

BY REGION, 2022–2029 (USD MILLION)   199

TABLE 82              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,

2022–2029 (USD MILLION)            201

TABLE 83              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ON-PREMISES DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)          202

TABLE 84              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CLOUD-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)          203

TABLE 85              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAAS-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)          205

TABLE 86              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER,

2022–2029 (USD MILLION)            207

TABLE 87              INDICATIVE LIST OF DEVELOPMENTS RELATED TO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY                208

TABLE 88              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)            209

TABLE 89              INDICATIVE LIST OF COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS             210

TABLE 90              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)                 211

TABLE 91              INDICATIVE LIST OF COLLABORATIONS IN RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES       211

TABLE 92              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2022–2029 (USD MILLION)            212

TABLE 93              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION,

2022–2029 (USD MILLION)            214

TABLE 94              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               216

TABLE 95              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PROCESS 2022–2029 (USD MILLION)  216

TABLE 96              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY USE CASE, 2022–2029 (USD MILLION)                217

TABLE 97              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)                217

TABLE 98              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                217

TABLE 99              NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          218

TABLE 100            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PLAYER TYPE, 2022–2029 (USD MILLION)        218

TABLE 101            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY AI TOOL, 2022–2029 (USD MILLION)  219

TABLE 102            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)                219

TABLE 103            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      220

TABLE 104            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2022–2029 (USD MILLION)               220

TABLE 105            US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS              221

TABLE 106            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS

2022–2029 (USD MILLION)            222

TABLE 107            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE,

2022–2029 (USD MILLION)            223

TABLE 108            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            223

TABLE 109            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            223

TABLE 110            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            224

TABLE 111            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            224

TABLE 112            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL,

2022–2029 (USD MILLION)            225

TABLE 113            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       225

TABLE 114            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            226

TABLE 115            US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 226

TABLE 116            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION)                 227

TABLE 117            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 228

TABLE 118            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)                 228

TABLE 119            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            228

TABLE 120            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          229

TABLE 121            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            229

TABLE 122            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 230

TABLE 123            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       230

TABLE 124            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            231

TABLE 125            CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 231

TABLE 126            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022–2029 (USD MILLION)                 232

TABLE 127            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 233

TABLE 128            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 233

TABLE 129            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            234

TABLE 130            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            234

TABLE 131            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          235

TABLE 132            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            235

TABLE 133            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 236

TABLE 134            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       236

TABLE 135            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      237

TABLE 136            EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2022–2029 (USD MILLION)               237

TABLE 137            UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS              238

TABLE 138            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS,

2022–2029 (USD MILLION)            239

TABLE 139            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 239

TABLE 140            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            240

TABLE 141            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            240

TABLE 142            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            241

TABLE 143            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            241

TABLE 144            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL,

2022–2029 (USD MILLION)            242

TABLE 145            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       242

TABLE 146            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            243

TABLE 147            UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 243

TABLE 148            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)            244

TABLE 149            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            244

TABLE 150            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)                245

TABLE 151            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                245

TABLE 152            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 246

TABLE 153            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            246

TABLE 154            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)            247

TABLE 155            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)            247

TABLE 156            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      248

TABLE 157            GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            248

TABLE 158            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 249

TABLE 159            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 250

TABLE 160            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            250

TABLE 161            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            250

TABLE 162            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          251

TABLE 163            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            251

TABLE 164            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 252

TABLE 165            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       252

TABLE 166            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      253

TABLE 167            FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 253

TABLE 168            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 254

TABLE 169            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 255

TABLE 170            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            255

TABLE 171            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            255

TABLE 172            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            256

TABLE 173            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            256

TABLE 174            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 257

TABLE 175            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       257

TABLE 176            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            258

TABLE 177            ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 258

TABLE 178            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 259

TABLE 179            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 259

TABLE 180            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            260

TABLE 181            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            260

TABLE 182            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            261

TABLE 183            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            261

TABLE 184            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 262

TABLE 185            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       262

TABLE 186            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            263

TABLE 187            SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 263

TABLE 188            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PROCESS, 2022–2029 (USD MILLION) 264

TABLE 189            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY USE CASE, 2022–2029 (USD MILLION)                264

TABLE 190            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)                265

TABLE 191            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                265

TABLE 192            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          266

TABLE 193            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PLAYER TYPE, 2022–2029 (USD MILLION)        266

TABLE 194            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY AI TOOL, 2022–2029 (USD MILLION)  267

TABLE 195            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)                267

TABLE 196            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      268

TABLE 197            REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2022–2029 (USD MILLION)               268

TABLE 198            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY COUNTRY 2022–2029 (USD MILLION)                270

TABLE 199            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PROCESS, 2022–2029 (USD MILLION) 271

TABLE 200            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY USE CASE, 2022–2029 (USD MILLION)                271

TABLE 201            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            272

TABLE 202            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                272

TABLE 203            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          273

TABLE 204            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PLAYER TYPE, 2022–2029 (USD MILLION)        273

TABLE 205            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY AI TOOL, 2022–2029 (USD MILLION)  274

TABLE 206            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)            274

TABLE 207            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      275

TABLE 208            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            275

TABLE 209            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 277

TABLE 210            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 277

TABLE 211            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            278

TABLE 212            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            278

TABLE 213            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            279

TABLE 214            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            279

TABLE 215            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 280

TABLE 216            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       280

TABLE 217            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            281

TABLE 218            JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 281

TABLE 219            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 282

TABLE 220            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 283

TABLE 221            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            283

TABLE 222            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            283

TABLE 223            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            284

TABLE 224            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            284

TABLE 225            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 285

TABLE 226            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       285

TABLE 227            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            286

TABLE 228            CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 286

TABLE 229            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 287

TABLE 230            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 288

TABLE 231            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            288

TABLE 232            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            288

TABLE 233            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            289

TABLE 234            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            289

TABLE 235            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 290

TABLE 236            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       290

TABLE 237            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)            291

TABLE 238            INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 291

TABLE 239            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)            292

TABLE 240            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            292

TABLE 241            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)         293

TABLE 242            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)       293

TABLE 243            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)                294

TABLE 244            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            294

TABLE 245            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)            295

TABLE 246            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 295

TABLE 247            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)             296

TABLE 248            REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            296

TABLE 249            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               297

TABLE 250            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PROCESS, 2022–2029 (USD MILLION) 298

TABLE 251            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY USE CASE, 2022–2029 (USD MILLION)                298

TABLE 252            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            299

TABLE 253            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                299

TABLE 254            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          300

TABLE 255            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PLAYER TYPE, 2022–2029 (USD MILLION)        300

TABLE 256            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY AI TOOL, 2022–2029 (USD MILLION)  301

TABLE 257            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)            301

TABLE 258            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      302

TABLE 259            LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2022–2029 (USD MILLION)               302

TABLE 260            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 303

TABLE 261            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 303

TABLE 262            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            304

TABLE 263            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)       304

TABLE 264            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)            305

TABLE 265            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            305

TABLE 266            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 306

TABLE 267            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       306

TABLE 268            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      307

TABLE 269            BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 307

TABLE 270            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)                 308

TABLE 271            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)                 308

TABLE 272            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)            309

TABLE 273            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)            309

TABLE 274            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          310

TABLE 275            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            310

TABLE 276            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)                 311

TABLE 277            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)       311

TABLE 278            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      312

TABLE 279            MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)                 312

TABLE 280            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)            313

TABLE 281            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            313

TABLE 282            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)         314

TABLE 283            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)       314

TABLE 284            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)                315

TABLE 285            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            315

TABLE 286            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)            316

TABLE 287            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 316

TABLE 288            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)             317

TABLE 289            REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            317

TABLE 290            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2022–2029 (USD MILLION)            318

TABLE 291            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)            319

TABLE 292            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            319

TABLE 293            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)         320

TABLE 294            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)       320

TABLE 295            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)                321

TABLE 296            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            321

TABLE 297            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)            322

TABLE 298            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 322

TABLE 299            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)             323

TABLE 300            MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            323

TABLE 301            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PROCESS, 2022–2029 (USD MILLION) 324

TABLE 302            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            325

TABLE 303            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)                325

TABLE 304            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)                325

TABLE 305            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          326

TABLE 306            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY PLAYER TYPE, 2022–2029 (USD MILLION)        326

TABLE 307            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY AI TOOL, 2022–2029 (USD MILLION)  327

TABLE 308            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)                327

TABLE 309            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY DEPLOYMENT, 2022–2029 (USD MILLION)      328

TABLE 310            GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2022–2029 (USD MILLION)               328

TABLE 311            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)            329

TABLE 312            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)            329

TABLE 313            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)         330

TABLE 314            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)       330

TABLE 315            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)                331

TABLE 316            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)            331

TABLE 317            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)            332

TABLE 318            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 332

TABLE 319            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)             333

TABLE 320            REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)            333

TABLE 321            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, JANUARY 2021–OCTOBER 2024                334

TABLE 322            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION            338

TABLE 323            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: USE CASE FOOTPRINT     343

TABLE 324            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PROCESS FOOTPRINT      344

TABLE 325            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: THERAPEUTIC AREA FOOTPRINT                 345

TABLE 326            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PLAYER TYPE FOOTPRINT              346

TABLE 327            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEPLOYMENT MODE FOOTPRINT                 347

TABLE 328            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGION FOOTPRINT         348

TABLE 329            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS              351

TABLE 330            ARTIFICIAL INTELLIGENCE IN DRUG DEVELOPMENT MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION            352

TABLE 331            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PRODUCT AND SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024   355

TABLE 332            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEALS,

JANUARY 2021–OCTOBER 2024   356

TABLE 333            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024        357

TABLE 334            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024  358

TABLE 335            NVIDIA CORPORATION: COMPANY OVERVIEW                 359

TABLE 336            NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    360

TABLE 337            NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES,

JANUARY 2021–OCTOBER 2024   361

TABLE 338            NVIDIA CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024  363

TABLE 339            EXSCIENTIA: COMPANY OVERVIEW        368

TABLE 340            EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED    369

TABLE 341            EXSCIENTIA: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        371

TABLE 342            EXSCIENTIA: DEALS, JANUARY 2021–OCTOBER 2024        371

TABLE 343            EXSCIENTIA: EXPANSIONS, JANUARY 2021–OCTOBER 2024  377

TABLE 344            EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   378

TABLE 345            GOOGLE: COMPANY OVERVIEW               380

TABLE 346            GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED             381

TABLE 347            GOOGLE: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        382

TABLE 348            GOOGLE: DEALS, JANUARY 2021–OCTOBER 2024                 383

TABLE 349            GOOGLE: EXPANSIONS, JANUARY 2021–OCTOBER 2024  384

TABLE 350            RECURSION: COMPANY OVERVIEW         385

TABLE 351            RECURSION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    386

TABLE 352            RECURSION: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        386

TABLE 353            RECURSION: DEALS, JANUARY 2021–OCTOBER 2024        387

TABLE 354            RECURSION: EXPANSIONS, JANUARY 2021–OCTOBER 2024  388

TABLE 355            INSILICO MEDICINE: COMPANY OVERVIEW                 390

TABLE 356            INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    390

TABLE 357            INSILICO MEDICINE: PRODUCT AND SOLUTION LAUNCHES AND DEVELOPMENTS, JANUARY 2021–OCTOBER 2024        392

TABLE 358            INSILICO MEDICINE: DEALS, JANUARY 2021–OCTOBER 2024  393

TABLE 359            INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   398

TABLE 360            SCHRÖDINGER, INC.: COMPANY OVERVIEW                 400

TABLE 361            SCHRÖDINGER, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    401

TABLE 362            SCHRÖDINGER, INC.: DEALS, JANUARY 2021–OCTOBER 2024  402

TABLE 363            SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   405

TABLE 364            BENEVOLENTAI: COMPANY OVERVIEW                 406

TABLE 365            BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED    407

TABLE 366            BENEVOLENTAI: DEALS, JANUARY 2021–OCTOBER 2024  407

TABLE 367            MICROSOFT CORPORATION: COMPANY OVERVIEW          409

TABLE 368            MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    410

TABLE 369            MICROSOFT CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024        411

TABLE 370            ATOMWISE INC.: COMPANY OVERVIEW 413

TABLE 371            ATOMWISE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    413

TABLE 372            ATOMWISE INC.: DEALS, JANUARY 2021–OCTOBER 2024  414

TABLE 373            ILLUMINA, INC.: COMPANY OVERVIEW 415

TABLE 374            ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    416

TABLE 375            ILLUMINA, INC.: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024   417

TABLE 376            ILLUMINA, INC.: DEALS, JANUARY 2021–OCTOBER 2024  418

TABLE 377            NUMEDII, INC.: COMPANY OVERVIEW   420

TABLE 378            NUMEDII, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    420

TABLE 379            XTALPI INC.: COMPANY OVERVIEW        421

TABLE 380            XTALPI INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    421

TABLE 381            XTALPI INC.: DEALS, JANUARY 2021–OCTOBER 2024        422

TABLE 382            IKTOS: COMPANY OVERVIEW    424

TABLE 383            IKTOS: PRODUCTS/SERVICES/SOLUTIONS OFFERED             425

TABLE 384            IKTOS: DEALS, JANUARY 2021–OCTOBER 2024                 426

TABLE 385            IKTOS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024        429

TABLE 386            TEMPUS: COMPANY OVERVIEW                430

TABLE 387            TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED             430

TABLE 388            TEMPUS: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        431

TABLE 389            TEMPUS: DEALS, JANUARY 2021–OCTOBER 2024                 432

TABLE 390            TEMPUS: EXPANSIONS, JANUARY 2021–OCTOBER 2024  435

TABLE 391            TEMPUS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024        435

TABLE 392            DEEP GENOMICS: COMPANY OVERVIEW                 436

TABLE 393            DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED    436

TABLE 394            DEEP GENOMICS: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024   437

TABLE 395            DEEP GENOMICS: DEALS, JANUARY 2021–OCTOBER 2024  437

TABLE 396            DEEP GENOMICS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   437

TABLE 397            VERGE GENOMICS: COMPANY OVERVIEW                 438

TABLE 398            VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED    438

TABLE 399            VERGE GENOMICS: DEALS, JANUARY 2021–OCTOBER 2024  439

TABLE 400            BENCHSCI: COMPANY OVERVIEW            440

TABLE 401            BENCHSCI: PRODUCTS/SERVICES/SOLUTIONS OFFERED             440

TABLE 402            BENCHSCI: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        441

TABLE 403            BENCHSCI: DEALS, JANUARY 2021–OCTOBER 2024        441

TABLE 404            BENCHSCI: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024        441

TABLE 405            INSITRO: COMPANY OVERVIEW                442

TABLE 406            INSITRO: PRODUCTS/SERVICES/SOLUTIONS OFFERED             442

TABLE 407            INSITRO: DEALS, JANUARY 2021–OCTOBER 2024                 443

TABLE 408            INSITRO: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024        443

TABLE 409            VALO HEALTH: COMPANY OVERVIEW   444

TABLE 410            VALO HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED    444

TABLE 411            VALO HEALTH: DEALS, JANUARY 2021–OCTOBER 2024  445

TABLE 412            VALO HEALTH: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   446

TABLE 413            BPGBIO, INC.: COMPANY OVERVIEW      447

TABLE 414            BPGBIO, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    447

TABLE 415            BPGBIO, INC.: DEALS, JANUARY 2021–OCTOBER 2024        448

TABLE 416            MERCK KGAA: COMPANY OVERVIEW     449

TABLE 417            MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED    450

TABLE 418            MERCK KGAA: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024        451

TABLE 419            MERCK KGAA: DEALS, JANUARY 2021–OCTOBER 2024        451

TABLE 420            MERCK KGAA: EXPANSIONS, JANUARY 2021–OCTOBER 2024  452

TABLE 421            MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024   453

TABLE 422            PREDICTIVE ONCOLOGY: COMPANY OVERVIEW          454

TABLE 423            IQVIA INC.: COMPANY OVERVIEW            455

TABLE 424            TENCENT HOLDINGS LIMITED: COMPANY OVERVIEW          456

TABLE 425            CYTOREASON LTD.: COMPANY OVERVIEW                 457

TABLE 426            OWKIN, INC.: COMPANY OVERVIEW       458

TABLE 427            CLOUD PHARMACEUTICALS: COMPANY OVERVIEW          459

TABLE 428            EVAXION BIOTECH A/S: COMPANY OVERVIEW                 460

TABLE 429            STANDIGM INC.: COMPANY OVERVIEW 461

TABLE 430            BIOAGE LABS: COMPANY OVERVIEW     462

TABLE 431            ENVISAGENICS: COMPANY OVERVIEW  463

TABLE 432            ABCELLERA: COMPANY OVERVIEW         464

TABLE 433            CENTELLA: COMPANY OVERVIEW           465

LIST OF FIGURES

FIGURE 1              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SEGMENTS AND REGIONS CONSIDERED                 40

FIGURE 2              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: YEARS CONSIDERED         42

FIGURE 3              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RESEARCH DESIGN            45

FIGURE 4              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:

KEY DATA FROM SECONDARY SOURCES               47

FIGURE 5              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY PRIMARY SOURCES   48

FIGURE 6              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:

KEY DATA FROM PRIMARY SOURCES     49

FIGURE 7              ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY INDUSTRY INSIGHTS                50

FIGURE 8              BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION                 50

FIGURE 9              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           51

FIGURE 10            SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS              52

FIGURE 11            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION 53

FIGURE 12            BOTTOM-UP APPROACH: END-USER SPENDING ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY    54

FIGURE 13            CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029)          57

FIGURE 14            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 58

FIGURE 15            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TOP-DOWN APPROACH  58

FIGURE 16            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DATA TRIANGULATION  59

FIGURE 17            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS,

2024 VS. 2029 (USD MILLION)      62

FIGURE 18            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE,

2024 VS. 2029 (USD MILLION)      63

FIGURE 19            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 63

FIGURE 20            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,

2024 VS. 2029 (USD MILLION)      64

FIGURE 21            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL,

2024 VS. 2029 (USD MILLION)      65

FIGURE 22            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,

2024 VS. 2029 (USD MILLION)      65

FIGURE 23            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER,

2024 VS. 2029 (USD MILLION)      66

FIGURE 24            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL SNAPSHOT     67

FIGURE 25            INCREASING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS TO DRIVE MARKET                 68

FIGURE 26            US AND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2023 69

FIGURE 27            INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029          70

FIGURE 28            NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD       71

FIGURE 29            EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD            71

FIGURE 30            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES          72

FIGURE 31            COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023          79

FIGURE 32            APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023             84

FIGURE 33            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS                87

FIGURE 34            EVOLUTION OF AI IN DRUG DISCOVERY MARKET               88

FIGURE 35            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: STRUCTURE-BASED DRUG DESIGNING                 90

FIGURE 36            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS     91

FIGURE 37            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS                93

FIGURE 38            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TYPES OF SERVICE             94

FIGURE 39            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS                 113

FIGURE 40            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS            115

FIGURE 41            KEY BUYING CRITERIA FOR TOP THREE END USERS   116

FIGURE 42            JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN DRUG DISCOVERY” PATENTS (JANUARY 2015–SEPTEMBER 2024) 117

FIGURE 43            MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (JANUARY 2015–SEPTEMBER 2024)      119

FIGURE 44            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BUSINESS MODELS            130

FIGURE 45            BENEFITS OF HYBRID BUSINESS MODELS                 131

FIGURE 46            SPECIALIZATION OF ARTIFICIAL INTELLIGENCE-BASED COMPANIES OVER TIME                131

FIGURE 47            FUNDING IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

2013–2022 (USD MILLION)            132

FIGURE 48            MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING LABORATORY INFORMATICS ACROSS INDUSTRIES                 134

FIGURE 49            IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS          136

FIGURE 50            HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2023        151

FIGURE 51            NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT          215

FIGURE 52            DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023)           221

FIGURE 53            ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT                270

FIGURE 54            REVENUE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2019–2023)          337

FIGURE 55            MARKET SHARE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2023)    338

FIGURE 56            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RANKING OF KEY MARKET PLAYERS (2023)    339

FIGURE 57            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023  341

FIGURE 58            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT   342

FIGURE 59            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                350

FIGURE 60            EV/EBITDA OF KEY VENDORS   352

FIGURE 61            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                353

FIGURE 62            ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:

BRAND/PRODUCT COMPARATIVE ANALYSIS     354

FIGURE 63            NVIDIA CORPORATION: COMPANY SNAPSHOT                 360

FIGURE 64            EXSCIENTIA: COMPANY SNAPSHOT        369

FIGURE 65            GOOGLE: COMPANY SNAPSHOT               381

FIGURE 66            RECURSION: COMPANY SNAPSHOT        385

FIGURE 67            SCHRÖDINGER, INC.: COMPANY SNAPSHOT                 401

FIGURE 68            BENEVOLENTAI: COMPANY SNAPSHOT                 406

FIGURE 69            MICROSOFT CORPORATION: COMPANY SNAPSHOT          410

FIGURE 70            ILLUMINA, INC.: COMPANY SNAPSHOT 416

FIGURE 71            MERCK KGAA: COMPANY SNAPSHOT     450

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧